V16.F · Virbac SA

-

Please sign in to comment on V16.F

1 Comment

Admin

4 years ago

Virbac SA is currently in a long term uptrend where the price is trading 35.3% above its 200 day moving average.

From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.

Virbac SA's total revenue sank by 0.0% to $237M since the same quarter in the previous year.

Its net income has dropped by 0.0% to $13M since the same quarter in the previous year.

Finally, its free cash flow fell by 30.9% to $34M since the same quarter in the previous year.

Based on the above factors, Virbac SA gets an overall score of 2/5.

Sector	Healthcare
Industry	Drug Manufacturers - General
Exchange	F
CurrencyCode	EUR
ISIN	FR0000031577

Market Cap	3B
PE Ratio	17.45
Target Price	None
Dividend Yield	0.4%
Beta	0.86

ABOUT

Virbac SA

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.

V16.F · Virbac SA

-

Virbac SA

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Virbac SA using a moving average strategy